Biogen Inc. (BIIB) Analyst Ratings & Price Targets

Biogen Inc.

BIIB · Nasdaq

Analyst Consensus

Buy

35 analysts

$216

Current

—

Low

$240

Average

—

High

Average target implies +11.31% versus the current price.

Analyst Ratings Synthesis

Consensus is Buy, with all 35 analysts supporting that rating. The only supplied target statistic is a mean of $238.50; low and high targets are unavailable, so the target cluster and width of the distribution cannot be established. No named analyst or bank is identified as most or least bullish. The evidence also reports no rating or target revisions during the week, leaving revision direction undetermined. The substantive disagreement behind the target range cannot be described from the supplied material: no individual estimates, rationales, or competing valuation views are provided. Accordingly, the consensus is clear, but its dispersion and recent change are not measurable here.

Rating Actions

No individual rating actions have been captured for BIIByet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Why Biogen Stock Topped the Market TodayThe Motley Fool
Bullish

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

BMO CAPITAL MKT

BTIG

CANACCORD GENUI

CANTOR FITZGERA

CO FORECST

EVERCORE ISI

GOLDMAN SACHS

GUGGENHEIM SEC.

H C WAINWRIGHT

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MIZUHO SECURITI

MORGAN STANLEY

NEEDHAM & CO.

OPPENHEIMER HLD

PIPER SANDLER

RAYMOND JAMES

RBC CAPITAL

ROTHSCHILD REDB

SCOTIABANK

STIFEL NICOLAUS

TD COWEN

TRUIST SECURITI

UBS

WEDBUSH SECURIT

WELLS FARGO SEC

WILLIAM BLAIR

WOLFE RESEARCH

ZACKS RESEARCH

Symbol: BIIB
Type: Stock
Sector: Health Care
Industry: Biological Products, (No Diagnostic Substances)
Exchange: Nasdaq

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at www.biogen.com . Follow us on social media - Facebook , Instagram , LinkedIn , X , YouTube .

Key Issues

Bullish view

Biogen handily beat analyst estimates on both the top and bottom lines, indicating that operating performance may be stronger than expectations embedded in the stock.

Bearish view

The evidence identifies only a single reported earnings beat and gives no detail on its magnitude, revenue mix, or durability; FY2025 net income was also below FY2024 despite higher revenue.

Analyst Consensus

See all

Buy

35 analysts

$216

Current

—

Low

$240

Average

—

High

Average target implies +11.31% versus the current price.

Earnings History

BeatMissNo estimate

Biogen Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers